[Clinical and functional aspects of obstructive respiratory syndromes following administration of a single dose of salbutamol in aerosol form].
30 subjects suffering from obstructive type chronic bronchopneumopathies were treated with salbutamol, a new Beta2 stimulating bronchodilator, administered by aerosol in a single dose of 200 gamma. Clinically the bronchospasm resolved itself or was reduced in just a few minutes in more than 70% of cases. Functionally, the various spirometric parameters were followed up for six hours and showed that the drug is capable of reducing flow resistance in rapid, lasting fashion, thus improving airway conductivity and making lung ventilation more homogeneous. No cardiovascular alterations were encountered.
D000336:Aerosols; D000368:Aged; D000402:Airway Obstruction / Q000188:drug therapy* / Q000503:physiopathology; D000420:Albuterol / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008448:Maximal Expiratory Flow Rate; D008875:Middle Aged; D012115:Residual Volume; D013147:Spirometry; D013577:Syndrome; D014797:Vital Capacity / Q000187:drug effects
D000336:Aerosols; D000420:Albuterol
Aspetti clinici e funzionali nelle sindromi respiratorie ostruttive dopo salbutamolo per aerosol dosato